Literature DB >> 30915644

Pharmacokinetics of First-Line Anti-Tubercular Drugs.

Aparna Mukherjee1, Rakesh Lodha2, S K Kabra1.   

Abstract

Determining the optimal dosages of isoniazid, rifampicin, pyrazinamide and ethambutol in children is necessary to obtain therapeutic serum concentrations of these drugs. Revised dosages have improved the exposure of 1st line anti-tubercular drugs to some extent; there is still scope for modification of the dosages to achieve exposures which can lead to favourable outcome of the disease. High dose of rifampicin is being investigated in clinical trials in adults with some benefit; studies are required in children. Inter-individual pharmacokinetic variability and the effect of age, nutritional status, Human immunodeficiency virus (HIV) infection, acetylator genotype may need to be accounted for in striving for the dosages best suited for an individual.

Entities:  

Keywords:  Anti tuberculosis drugs; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin

Mesh：

Substances：

Year:  2019        PMID： 30915644     DOI： 10.1007/s12098-019-02911-w

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  68 in total

1.  Systematic treatment of primary tuberculosis.

Authors:  R DEBRE
Journal:  Am Rev Tuberc       Date:  1956-08

2.  Pyrazinamide plasma concentrations in young children with tuberculosis.

Authors:  Helen McIlleron; Marianne Willemse; Hendrik Simon Schaaf; Peter John Smith; Peter Roderick Donald
Journal:  Pediatr Infect Dis J       Date:  2011-03       Impact factor: 2.129

3.  Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.

Authors:  L M Verhagen; D López; P W M Hermans; A Warris; R de Groot; J F García; J H de Waard; R E Aarnoutse
Journal:  Trop Med Int Health       Date:  2012-10-24       Impact factor: 2.622

4.  Rifampin and rifabutin and their metabolism by human liver esterases.

Authors:  C A Jamis-Dow; A G Katki; J M Collins; R W Klecker
Journal:  Xenobiotica       Date:  1997-10       Impact factor: 1.908

5.  Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.

Authors:  Helen McIlleron; Marianne Willemse; Cedric J Werely; Gregory D Hussey; H Simon Schaaf; Peter J Smith; Peter R Donald
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

6.  Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.

Authors:  Pooja Gupta; Vandana Roy; Gulshan Rai Sethi; Tarun Kumar Mishra
Journal:  Br J Clin Pharmacol       Date:  2007-12-17       Impact factor: 4.335

7.  Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; T Kannan; P K Bhavani; S Ramesh Kumar; N Poorana Gangadevi; V V Banurekha; V Sudha; S Venkatesh; N Ravichandran; S Kalpana; G Mathevan; G N Sanjeeva; Dipti Agarwal; Soumya Swaminathan
Journal:  Pediatr Infect Dis J       Date:  2016-05       Impact factor: 2.129

8.  Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.

Authors:  Derek J Sloan; Andrew D McCallum; Alessandro Schipani; Deirdre Egan; Henry C Mwandumba; Steve A Ward; David Waterhouse; Gertrude Banda; Theresa J Allain; Andrew Owen; Saye H Khoo; Geraint R Davies
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

9.  Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.

Authors:  Neesha Rockwood; Jotam G Pasipanodya; Paolo Denti; Frederick Sirgel; Maia Lesosky; Tawanda Gumbo; Graeme Meintjes; Helen McIlleron; Robert J Wilkinson
Journal:  Clin Infect Dis       Date:  2017-05-15       Impact factor: 9.079

10.  Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.

Authors:  Blessed Winston Aruldhas; Richard M Hoglund; Jaya Ranjalkar; Joel Tarning; Sumith K Mathew; Valsan Philip Verghese; Anuradha Bose; Binu Susan Mathew
Journal:  Br J Clin Pharmacol       Date:  2019-01-17       Impact factor: 4.335
View more
  2 in total

1.  Advances in Tuberculosis: Diagnostics.

Authors:  Varinder Singh; Sushil K Kabra
Journal:  Indian J Pediatr       Date:  2019-04-03       Impact factor: 1.967

2.  LipF increases rifampicin and streptomycin sensitivity in a Mycobacterium tuberculosis surrogate.

Authors:  Ana Leticia Arriaga-Guerrero; Carlos E Hernández-Luna; Joyce Rigal-Leal; Rene J Robles-González; Laura Adiene González-Escalante; Beatriz Silva-Ramírez; Roberto Mercado-Hernández; Javier Vargas-Villarreal; Mario Bermúdez de León; Katia Peñuelas-Urquides
Journal:  BMC Microbiol       Date:  2020-05-25       Impact factor: 3.605
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.